Yu, Eric
Ambati, Aditya http://orcid.org/0000-0001-8462-3552
Andersen, Maren Stolp
Krohn, Lynne http://orcid.org/0000-0001-6554-1666
Estiar, Mehrdad A.
Saini, Prabhjyot
Senkevich, Konstantin http://orcid.org/0000-0003-3407-5716
Sosero, Yuri L.
Sreelatha, Ashwin Ashok Kumar
Ruskey, Jennifer A.
Asayesh, Farnaz
Spiegelman, Dan
Toft, Mathias
Viken, Marte K.
Sharma, Manu
Blauwendraat, Cornelis http://orcid.org/0000-0001-9358-8111
Pihlstrøm, Lasse http://orcid.org/0000-0002-7635-8645
Mignot, Emmanuel
Gan-Or, Ziv http://orcid.org/0000-0003-0332-234X
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson’s Research
Canada First Research Excellence Fund
Parkinson Canada
Fonds de Recherche du Québec - Santé
South-Eastern Regional Health Authority, Norway
Canada First Research Excellence Fund
Article History
Received: 23 April 2021
Accepted: 30 August 2021
First Online: 21 September 2021
Competing interests
: Mathias Toft—Dr. Toft received grants from Norwegian Parkinson Research Fund and Reberg’s legacy. Lasse Pihlstrøm—Dr. Pihlstrøm received grants from National Health Association, Norway, and South-Eastern Regional Health Authority, Norway. Emmanuel Mignot—Dr. Mignot reports consultancies from Idorsia Pharmaceuticals Ltd., personal fees from Jazz Pharmaceutical, Alairion, ALPCO, INEXIA, Merck, Orexia, Rhythm, and Sunovion. Ziv Gan-Or—Dr. Gan-Or reports personal fees from Idorsia, Neuron23, Handl Therapeutics, Lysosomal Therapeutics Inc., Deerfield, Lighthouse, Prevail Therapeutics, Ono Therapeutics, Denali, and Inception Science. Eric Yu, Aditya Ambati, Maren Stolp Andersen, Lynne Krohn, Mehrdad A. Estiar, Prabhjyot Saini, Konstantin Senkevich, Yuri L. Sosero, Ashwin Ashok Kumar Sreelatha, Jennifer A. Ruskey, Farnaz Asayesh, Dan Spiegelman, Marte K. Viken, Manu Sharma, and Cornelis Blauwendraat report no relevant disclosures.